Lantheus Holdings, Inc. (LNTH)
| Market Cap | $6.68B+90.5% |
| Revenue (ttm) | $1.56B |
| Net Income | $269.90M |
| EPS | $4.02 |
| Shares Out | 65.40M |
| PE Ratio | 25.40 |
| Forward PE | 15.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,067,788 |
| Open | $102.10 |
| Previous Close | $102.10 |
| Day's Range | $102.07 - $102.40 |
| 52-Week Range | $54.94 - $111.86 |
| Beta | 0.03 |
| Analysts | Hold |
| Price Target | $105.99(+3.81%) |
| Earnings Date | Nov 5, 2026 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Analyst consensus
1 firm rating LNTH in the last 3 months, one vote each. Issuer-paid research is not counted.
$LNTH stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of LNTH by members of U.S. Congress
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Oct 15, 2026 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Oct 14, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 28, 2025 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 28, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 27, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 13, 2025 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 13, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 12, 2025 |
Recently reported changes in LNTH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LNTH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LNTH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LNTH Revenue by Segment or Geography
| Product revenue, net | $378.37M | 48.52% |
| PYLARIFY | $238.93M | 30.64% |
| DEFINITY | $85.67M | 10.99% |
| Neuraceq | $45.58M | 5.84% |
| Strategic partnerships and other revenue | $19.73M | 2.53% |
| License and royalty revenues | $11.55M | 1.48% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LNTH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LNTH from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from LNTH’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive pipeline progress with Phase 3 Alzheimer's data presentation and strategic asset sale to strengthen core business focus.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| ZIG | The Acquirers Fund | 3.25% |
| MNA | NYLI Merger Arbitrage ETF | 3.05% |
| MRGR | ProShares - Merger ETF | 2.30% |
| ARB | AltShares Merger Arbitrage ETF | 2.00% |
| GRPM | Invesco S&P MidCap 400 GARP ETF | 1.97% |
| EWMC | Invesco S&P MidCap 400 Equal Weight ETF | 1.97% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.53% |
| IVSS | Applied Finance IVS US SMID ETF | 1.06% |
| EVNT | AltShares Event-Driven ETF | 0.99% |
| MCOW | Pacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 0.81% |
| FLQS | Franklin U.S. Small Cap Multifactor Index ETF | 0.79% |
| HIAI | ETF Opportunities Trust - Ai Funds High Conviction US Equity AI-Managed ETF | 0.77% |
Weight is the stock’s share of each fund’s holdings.
